Results

HYPOTHALAMO-PITUITARY FUNCTION AT
PRESENTATION
Symptoms
Symptoms at presentation referable to hypothalamo-pituitary dysfunction are shown in table 1. Although endocrine symptoms were infrequent as a presenting complaint, there was a history of poor growth in one third of the patients preceding the diagnosis by a mean of 2.9 years (range 0.5 to 5.0 years). Of the 10 patients with growth failure as the presenting complaint, eight were aged 10 years or over at diagnosis. All four children with a history of lethargy and frequent, prolonged infections were adrenocorticotrophic hormone (ACTH) deficient on preoperative testing. Two children, aged 2.2 and 2.7 years, with evidence of hypopituitarism at diagnosis had a history of prolonged seizures, resistant to anticonvulsants, in association with intercurrent illness. 
Of the nine children who subsequently died, two (aged 2.3 and 2.5 years) died suddenly and unexpectedly at home after acute intercurrent illnesses, 1.2 and 0.3 years from surgery, respectively. Inadequate cortisol replacement and absorption with associated hypoglycaemia at the time of infection were thought to be direct contributors to their deaths.
Posterior pituitary function After surgery, 93% of patients developed diabetes insipidus and this was permanent in 80% of cases (table 2) . At follow up assessment, 14 of the 66 survivors were not taking intranasal desmopressin, although three patients had symptoms and biochemistry to suggest mild diabetes insipidus and two others were taking carbamazepine for epilepsy which coincidentally may have 'treated' partial ADH deficiency. MRI showed normal calibre pituitary stalks in two, and thinned but visible stalks in four out of 63 patients at follow up assessment; ofthese only three retained normal function.
After attempted radical surgery, 10 children developed diabetes insipidus with an absent or impaired sense of thirst. All had other evidence of significant hypothalamic dysfunction. Maintenance of osmotic balance was precarious with recurrent episodes of hypernatraemia and hyponatraemia; two patients had major thrombotic events requiring full anticoagulation. Mean length of stay in hospital after surgery for these patients was 17 weeks (range 4.0 to 46.0 weeks). Six children subsequently died from 0.4 to 15.4 years (mean 7.8 years) after initial surgery and in one other of the total of nine deaths, there was evidence of extrapontine myelinolysis at necropsy. At the time of follow up assessment, 60 patients had received or were receiving GH treatment. Thirty one patients (41%) had one or more tumour recurrences from 0.2 to 9.4 years (mean 1.9 years) from initial surgery; 25 recurrences occurred within the first three years from operation. The mean time from surgery to start of GH treatment for the 60 patients treated with GH was 2.0 years (range 0.2 to 9.5 years) with a total time elapsed of 117 patient years before start of treatment. Mean duration of GH treatment was 4.9 years per patient (range 0.2 to 14.7 years) with a total of 292 treatment years. Of the 31 recurrences, 23 patients had either never received GH treatment (six cases) or tumour recurred before start of GH treatment (17 cases) compared with eight patients with recurrence while on GH (Fisher's exact test, p < 0.0005). There was no difference in the mean time on or off GH between 35 patients treated with GH and not having a recurrence and the eight patients with tumour recurrence while taking GH.
I
Puberty
At follow up assessment a total of 48 patients had either entered or completed puberty. In 42 out of 45 children who were prepubertal before diagnosis, onset of puberty was induced at a mean chronological age of 13.3 years (range 10.5 to 18.2 years) in 17 girls and a mean chronological age of 13.5 years (range 11.2 to 17.2 years) in 25 boys.
Three boys had spontaneous onset of puberty after surgery: one had attained adult secondary sexual characteristics, one had stage 4 genitalia and 12 ml testicular volumes, and the third was in early puberty (5 ml testicular volumes) at follow up assessment. Two out of the three were GH deficient/insufficient, one of whom was also TSH deficient.
Of nine girls achieving final height in whom puberty was induced, only one attained full adult sexual maturation, pubic hair development remaining at stage 3 or less in seven cases and axillary hair development remaining at stage 1 in six cases. Of 15 boys reaching final height in whom puberty was induced, 11 achieved stage 5 genitalia, nine stage 5 pubic hair, and nine stage 3 axillary hair. Testicular volumes increased marginally to 3 ml (two cases) and to 4 ml (one case) with testosterone esters alone. with a mean height SDS (-0.8 (1.5)) significantly lower than their corrected mid-parental height SDS ( + 0.1 (0.8)) (p = 0.003). Figure 2 shows that despite a history of growth failure preceding the diagnosis by a mean of 2.4 years in 1 1 of these patients and all but two requiring GH replacement after surgery, the predominant loss in height potential in relation to genetic target height occurred during the pubertal years. Four of the nine girls and 11 of the 16 boys achieved final heights within the 95% confidence limits of their mid-parental heights. All but two girls were below the 10th centile for the normal population whereas half of the boys were at or above the 50th centile at final height. The differences between the girls and boys are further demonstrated in fig 3 .
Although the pattern of growth from diagnosis to onset or induction of puberty and to final height was similar for both boys and girls, the girls were shorter at all stages than the boys and final height was significantly less (p = 0.002) than their corrected mid-parental height (mean difference (SEM) of 1.26 SD (0.27) between final height and mid-parental height). Mean chronological age for the girls was 8.9 years at diagnosis, 11.7 years at start of GH treatment, and 14.6 years at onset or induction of puberty, as compared with 6.5, 8.8, and 13.6 years for the boys, respectively. Mean body segment measurements are shown for 18 patients (seven girls and 1 1 boys) at induction of puberty and at final height in table 3. Chronological age at induction of puberty was from 11.4 to 17.9 years (mean 14.4 years) for the girls and from 11.2 to 17.2 years (mean 13.5 years) for the boys. There was disproportion with a short upper segment relative to leg length in both boys and girls at onset of puberty but the discrepancy between sitting height and subischial leg length was only significant in the girls (p = 0.02). In both sexes, the difference in segmental proportions present at induction of puberty did not alter significantly at final height, that is, there was no catch-up growth in the upper segment during puberty (table 3) . The chronically hyperosmolar child with an impaired sense of thirst is a complication exclusive to radical surgery, contributing significantly to the disabling hypothalamic damage found in up to 57% of cases in various reported series22 and thus to overall morbidity and mortality. The latter is poignantly illustrated by Katz's follow up data23 of Matson's series of patients,24 whereby a policy of attempted radical tumour resection in all patients resulted in nine out of 14 (64%) nonoperative deaths being directly attributable to the metabolic consequences of hypothalamic damage. Despite management of our patients with a fixed daily fluid intake and small, regular (twice or three times daily) doses of desmopressin, fluid balance remained unstable, as reflected by the prolonged hospital stays after surgery of up to 10-11 months in some cases and the high proportion of eventual deaths in these children.
The well recognised but incompletely understood phenomenon of 'growth without growth hormone'2"27 is known to be closely associated with, but not exclusive to,2 patients manifesting excessive weight gain after surgical intervention, obesity being reported in up to 60% of children following radical surgery for craniopharyngioma.' 20 Our data suggest that those patients showing catch-up growth are those with the most pronounced weight gain after surgery. However, Schoenle et al recently found no correlation between growth velocity and BMI or skinfold thickness (although numbers of patients were small).28
Although 15-68% of patients have been shown to grow at a normal or accelerated height velocity despite GH deficiency after surgery,"4 the majority of children eventually require substitution GH treatment. The question as to whether the mitogenic effects of GH influence tumour recurrence rate therefore remains important to establish with continued long term surveillance. Our data concur with the evidence so far that GH treatment does not increase the risk of craniopharyngioma recurrence.29 30 Although in terms of final height attainment, our patients have done better than previously reported by Burns et al," with 60% of subjects achieving final heights above the lower limits to be expected from their parental heights, this was seen predominantly in the boys, the girls falling significantly short of their genetic height potential. Their relatively older age at diagnosis when they were already shorter than the boys and the then later onset of GH treatment may have partly accounted for this, although our data suggest that height potential was lost for both sexes during the pubertal years rather than in prepuberty. We have no explanation for the latter but this may be related to GH dose, as both sex steroids and GH are required for optimal growth during puberty but little is known of the correct replacement doses of GH to use.32 In addition, some patients were initially treated with the now obsolescent dose regimens used with cadaver derived pituitary GH. Body segment disproportion was also greater in the girls and in both sexes there was inadequate upper segment growth during puberty such that the degree of disproportion present at induction of puberty was not improved by final height. This may reflect the same phenomenon seen in boys and girls with constitutional delayed puberty,33 particularly as many of the patients reaching final height had puberty induced at a later age than we would now routinely advocate. It remains to be seen whether normal growth and pubertal development are possible in the majority of patients with optimal institution of GH and sex steroid replacement. Certainly, an increase in upper segment growth to equal that of the lower would permit final height to be appropriate for genetic potential.
In conclusion, the endocrine morbidity in association with craniopharyngioma and its treatment remains high but in most cases should be manageable with appropriate hormonal replacement and continued patient and parent education. However, the extreme metabolic consequences of irreversible hypothalamic damage due to aggressive surgery, particularly combined ADH insufficiency and absent thirst, should prompt neurosurgeons to preserve hypothalamic function at all costs, especially as other treatment options, such as radiotherapy, may offer excellent long term tumour control.
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